[Intestinal bacterial colonisation and translocation in C3H/HeJ conventional mice fed a unique dose of live or dead Bifidobacterium breve C50].

The efficiency and safety of use of Bifidobacterium breve C50 (BbC50), a potential probiotic, was assessed as regards intestinal microbial colonisation and bacterial translocation. A suspension of BbC50, containing 1-5 to 107-108 live bacteria, was fed to C3H/HeJ mice. The passage of live BbC50 was not demonstrated by culture either in the intestine or extra-intestinal organs.

Partial characterization of bifidobacterium breve C50 cell-free whey compounds inducing modifications to the intestinal microflora.

Cell-free whey obtained from milk fermented with Bifidobacterium breve C50 (Bb C50) has been shown to modify the intestinal flora in humans and mice. Previous work showed that no antibiotic-like or barrier effect due to overgrowing bifidobacteria was implied in the microbial modifications. The present study was focused on characterizing the compounds and mechanisms involved.

Bacterial microleakage of Cavit, IRM, TERM, and Fermit: a 21-day in vitro study.

The aim of our study was to evaluate the leakage of four cements (Cavit, IRM, TERM, and Fermit) using a two-compartment model system and Streptococcus sanguis as bacterial marker. Access cavities in premolars were filled with cement and the teeth immersed in culture medium in the model system. Half of the teeth were thermocycled on day 2.

Cell-free whey from milk fermented with Bifidobacterium breve C50 used to modify the colonic microflora of healthy subjects.

The ingestion of viable bacteria is thought to be required to modify intestinal microflora. In the present study, the effects on fecal flora of consumption of cell-free concentrated whey from milk that had been fermented with Bifidobacterium breve C50 was tested using 10 healthy human volunteers. Results were compared with effects of a commercial milk formula that had been fermented with Streptococcus thermophilus and B.